GENFIT : Corporate presentation: Petit résumé généré par l IA

osaffer

15 novembre 2024 •10:00

Based on the corporate update provided by GENFIT, here are the key points regarding the expected data for GNS561:
GNS561 in KRAS-mutated cholangiocarcinoma

A phase 1b/2a clinical trial for GNS561 is currently ongoing1
.
Preliminary data from the Phase 1b portion of this trial is targeted to be available by the end of 20241
2
.
Final data from the full phase 1b/2a study is expected by the end of 20251
2
.

This timeline indicates that GENFIT is making progress with the clinical development of GNS561 for cholangiocarcinoma (bile duct cancer) with KRAS mutations. The company plans to have initial results from the early phase study within about a year, with more comprehensive data following approximately a year later. These upcoming readouts will provide important insights into the safety and potential efficacy of GNS561 in this specific type of cancer.

osaffer

15 novembre 2024 •10:02

Based on the information provided in the search results, we can estimate the cost of studies led by GENFIT as follows:
Research and Development Expenses
GENFIT is currently conducting several research and development programs, which include:

UNVEIL-IT™, a Phase 2 clinical trial evaluating VS-01 in Acute-on-Chronic Liver Failure (ACLF)
The cholangiocarcinoma program evaluating GNS561
The ACLF program evaluating NTZ
Non-clinical trial of SRT-015 in ACLF
ELATIVE®, specifically the portion of the Phase 3 clinical trial evaluating elafibranor in PBC not yet transferred to Ipsen

Financial Outlook
GENFIT expects that their existing cash and cash equivalents will enable them to fund their operating expenses and capital expenditure requirements until approximately the fourth quarter of 20251
2
. As of December 31, 2023, the company's cash and cash equivalents amounted to €77.8 million1
.
Upcoming Clinical Trials
GENFIT plans to initiate multiple clinical studies in 2025, including:

Two new proof-of-concept studies evaluating VS-01 and NTZ
A First-in-Human study for SRT-015 with GENFIT's formulation
Continuation of the Phase 2 UNVEIL-IT trial

These trials are expected to launch in the first half of 2025, with data readouts expected by year-end4
.
Estimated Costs
While specific costs for each study are not provided, we can infer that the total cost for all studies is significant, given that it accounts for a substantial portion of the company's cash burn rate. The fact that GENFIT expects their current cash position to fund operations until Q4 2025, including these new and ongoing studies, suggests that the total cost for all studies is likely in the tens of millions of euros. It's important to note that this is an estimation based on the available information. The actual costs may vary depending on factors such as the duration and complexity of each study, the number of patients enrolled, and any unforeseen challenges that may arise during the clinical trial process.

galais.j

15 novembre 2024 •10:07

Attention!

noenad

15 novembre 2024 •10:49

ah oui on a tout compris !!

VDBRob

15 novembre 2024 •12:01

Quelqu'un sait nous faire un résumé avec transcription ? 😂

LEOJOU8

15 novembre 2024 •12:23

GENFIT montre une stratégie claire : partenariat solide avec Ipsen pour la PBC, pipeline diversifié en ACLF et CCA, et trésorerie maîtrisée jusqu'à 2025. Les prochains readouts seront décisifs pour confirmer cette dynamique